Literature DB >> 17851120

Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy.

Marie Stiborová1, Eva Frei2, Volker M Arlt3, Heinz H Schmeiser2.   

Abstract

Aristolochic acid (AA), a naturally occurring nephrotoxin and carcinogen, is associated with tumor development in patients suffering from Chinese herbs nephropathy (now termed aristolochic acid nephropathy, AAN) and may also be a cause for the development of a similar type of nephropathy, the Balkan endemic nephropathy (BEN). Major DNA adducts [7-(deoxyadenosin-N6-yl)-aristolactam and 7-(deoxyguanosin-N2-yl)aristolactam] formed from AA after reductive metabolic activation were found in renal tissues of patients with both diseases. Understanding which human enzymes are involved in AA activation and/or detoxication is important in the assessment of an individual's susceptibility to this plant carcinogen. This paper reviews major hepatic and renal enzymes responsible for AA-DNA adduct formation in humans. Phase I biotransformation enzymes play a crucial role in the metabolic activation of AA to species forming DNA adducts, while a role of phase II enzymes in this process is questionable. Most of the activation of AA in human hepatic microsomes is mediated by cytochrome P450 (CYP) 1A2 and, to a lower extent, by CYP1A1; NADPH:CYP reductase plays a minor role. In human renal microsomes NADPH:CYP reductase is more effective in AA activation. Prostaglandin H synthase (cyclooxygenase, COX) is another enzyme activating AA in human renal microsomes. Among the cytosolic reductases, NAD(P)H:quinone oxidoreductase (NQO1) is the most efficient in the activation of AA in human liver and kidney. Studies with purified enzymes confirmed the importance of CYPs, NADPH:CYP reductase, COX and NQO1 in the AA activation. The orientation of AA in the active sites of human CYP1A1, -1A2 and NQO1 was predicted from molecular modeling and explains the strong reductive potential of these enzymes for AA detected experimentally. We hypothesized that inter-individual variations in expressions and activities of enzymes activating AA may be one of the causes responsible for the different susceptibilities to this carcinogen reflected in the development of AA-induced nephropathies and associated urothelial cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851120     DOI: 10.1016/j.mrrev.2007.07.003

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  31 in total

Review 1.  Chronic kidney disease and cancer: a troubling connection.

Authors:  Benedicte Stengel
Journal:  J Nephrol       Date:  2010 May-Jun       Impact factor: 3.902

2.  Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy.

Authors:  Bicheng Chen; Yongheng Bai; Mei Sun; Xiaojie Ni; Yunxiu Yang; Yirong Yang; Shaoling Zheng; Feifei Xu; Shengchuan Dai
Journal:  Int Urol Nephrol       Date:  2011-11-25       Impact factor: 2.370

3.  Aristolochic acid I metabolism in the isolated perfused rat kidney.

Authors:  Horacio A Priestap; M Cecilia Torres; Robert A Rieger; Kathleen G Dickman; Tomoko Freshwater; David R Taft; Manuel A Barbieri; Charles R Iden
Journal:  Chem Res Toxicol       Date:  2011-12-14       Impact factor: 3.739

4.  Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2.

Authors:  Marie Stiborová; Katerina Levová; Frantisek Bárta; Zhanquan Shi; Eva Frei; Heinz H Schmeiser; Daniel W Nebert; David H Phillips; Volker M Arlt
Journal:  Toxicol Sci       Date:  2011-11-15       Impact factor: 4.849

5.  Identification of a reduction product of aristolochic acid: implications for the metabolic activation of carcinogenic aristolochic acid.

Authors:  Horacio A Priestap; Carlos de los Santos; J Martin E Quirke
Journal:  J Nat Prod       Date:  2010-12-08       Impact factor: 4.050

6.  Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors.

Authors:  Kerstin Stemmer; Heidrun Ellinger-Ziegelbauer; Hans-Jürgen Ahr; Daniel R Dietrich
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 7.  p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.

Authors:  Neda Slade; Ute M Moll; Branko Brdar; Arijana Zorić; Bojan Jelaković
Journal:  Mutat Res       Date:  2009-02-04       Impact factor: 2.433

8.  New Approaches for Biomonitoring Exposure to the Human Carcinogen Aristolochic Acid.

Authors:  Byeong Hwa Yun; Viktoriya S Sidorenko; Thomas A Rosenquist; Kathleen G Dickman; Arthur P Grollman; Robert J Turesky
Journal:  Toxicol Res (Camb)       Date:  2015-07-01       Impact factor: 3.524

9.  beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism.

Authors:  Ying Xiao; Xiang Xue; Yuan-feng Wu; Guo-zheng Xin; Yong Qian; Tian-pei Xie; Li-kun Gong; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

10.  DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells.

Authors:  Sivaprasad Attaluri; Radha R Bonala; In-Young Yang; Mark A Lukin; Yujing Wen; Arthur P Grollman; Masaaki Moriya; Charles R Iden; Francis Johnson
Journal:  Nucleic Acids Res       Date:  2009-10-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.